Ehsan Project (EHSAN), a phase III clinical trial, was started in 2020 with the implementation of its first round of studies. EHSAN was approved in 2019 with the support of the National Institute for Development of Medical Sciences Research of Iran (NIMAD) and the participation of Shahid Sadoughi University of Medical Sciences and Yazd Cardiovascular Research Center. In this project, we collect. processes, and analyzes data on the effect (and side effects) of the drug “Synaptazine” in people over the age of 50 diagnosed with early-stage Alzheimer’s disease”.